Welcome to our dedicated page for Alpha Tau Medical Ltd. Ordinary Shares news (Ticker: $DRTS), a resource for investors and traders seeking the latest updates and insights on Alpha Tau Medical Ltd. Ordinary Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alpha Tau Medical Ltd. Ordinary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alpha Tau Medical Ltd. Ordinary Shares's position in the market.
Alpha Tau Medical presented new preclinical data at the 2024 ESTRO Congress, showcasing the abscopal immune effect of Alpha DaRT in pancreatic murine tumor models. The data revealed a significant reduction in distant tumor growth rate, indicating potential benefits for future clinical trials and patient outcomes. CEO Uzi Sofer highlighted the promising results, emphasizing the therapy's potential in combination with immunotherapy.
Alpha Tau Medical announced that CFO Raphi Levy will present at investor conferences in May 2024. The company, known for its alpha-radiation cancer therapy Alpha DaRT™, will participate in events like Guggenheim Securities Radiopharmaceuticals Day and H.C. Wainwright BioConnect Investor Conference.